Pipeline

R&D nke Sorrento lekwasịrị anya na ịnya ụgbọ ala ọhụrụ na COVID-19, ọgwụgwọ ọrịa kansa, njikwa mgbu zuru oke na ọrịa autoimmune.

Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
Mmemme COVID-19  

COVISTIX™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa

*

Ikike iji ihe mberede (EUA) na Mexico (COFEPRIS), Brazil (ANVISA), na CE akara na Europe.

COVIMARK™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa

*

Ngwa etinyere na US na Canada maka ikike iji ihe mberede (EUA)

VIREX (nchọpụta nchọpụta) N'ụlọ nyocha

60.2%*

EUA Enabling Studies in Q3 2022

OQORY™ (COVI-MSC) ARDS n'ihi COVID-19 n'ime ndị ọrịa ICU

82%*

Ọnwụnwa dị mkpa na Brazil

                         
OVYDSO (Olgotrelvir)Ọrịa mgbochi (Oral pill)

40%*

Omicron mRNA ogwu Vaccine

20%*

Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
immunotherapy  

FUJOVEE (Abivertinib) NSCLC

82%*

FUJOVEE (Abivertinib) B cell Lymphomas

60.2%*

FUJOVEE (Abivertinib) Prostate

20%*

PD-L1 (Socazolimab)* SCLC

82%*

* Na mmekorita ya na Lee's Pharm na China

PD-L1 (STI-3031)** Ọrịa Cervical

82%*

** Na US yana mmekorita ya na ImmuneOncia na Korea

CD47 Tumor siri ike

40%*

CD38 DAR-T multiple Myeloma

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, na esophageal

40%*

TROP2 ADC* Tumor siri ike

40%*

Seprehvec™ oncolytic nje Tumor siri ike; CNS Tumor

40%*

Ọnụ ego nke BCMA ADC Tumor Liquid

20%*

Bevacizumab-ADNAB™ Ọrịa kansa Endometrial

40%*

Na mmekorita ya na Mayo Clinic

Bevacizumab-ADNAB™ Ọrịa Ovarian

40%*

Na mmekorita ya na Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

Na mmekorita ya na Mayo Clinic

Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma

40%*

Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
Pain  

ZTlido® 1.8%
Neuralgia Postherpetic - PHN

99.8%*

Gloperba®
Ọgwụgwọ gout (Oral)

99.8%*

SEMEXA (SP-102) Lumbar Radicular/Sciatica mgbu

82%*

SP-103 (Sistemụ Topical Lidocaine 5.4%) Nnukwu Mgbu mgbu

60.2%*

SP-104 (Naltrexone obere dose gbawara egbu oge) Fibromyalgia

20%*

RTX (resiferatoxin)
Epidural injection
Ihe mgbu na-adịghị agwụ agwụ na ọrịa kansa dị elu

60.3%*

Nhọpụta nwa mgbei

RTX (resiferatoxin)
Ụzọ intra-articular
OA Mgbu OA Na-agafeghị agafe ruo Dị Ike

60.2%*

Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
Nnyefe ọgwụ Lymphatic  

Sofusa® mgbochi TNF Autoimmune (RA)

40%*

Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma

40%*

Sofusa® mgbochi CTLA-4 Melanoma

40%*

Na mmekorita ya na Mayo Clinic
Mmemme COVID-19
Mmemme igodo (Ngosipụta) adọ
COVISTIX™ (nchọpụta nchọpụta) FDA EUA
COVIMARK™ (nchọpụta nchọpụta) FDA EUA
VIREX (nchọpụta nchọpụta) PH III
FUJOVEE (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
OVYDSO (Olgotrelvir) Ph II
Omicron mRNA ogwu Mgbochi
immunotherapy
Mmemme igodo (Ngosipụta) adọ
FUJOVEE (Abivertinib) Ph III
FUJOVEE (Abivertinib) Ph II
FUJOVEE (Abivertinib) Mgbochi
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 Tumor siri ike Ph I
CD38 DAR-T (Otu Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, na esophageal) Ph I
TROP2 ADC* Tumor siri ike Ph I
Seprehvec™ oncolytic nje Tumor siri ike (CNS Tumors) PH I
Ọnụ ego nke BCMA ADC ( Tumor Liquid) Mgbochi
Bevacizumab-ADNAB™ (ọrịa cancer endometrial) Ph I
Bevacizumab-ADNAB™ (ọrịa cancer ovarian) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma Ph I
Pain
Mmemme igodo (Ngosipụta) adọ
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) Nkwado FDA
Gloperba® 1.8% Ọgwụgwọ gout (Oral) Nkwado FDA
SEMEXA (SP-102) Ph III
SP-103 (Sistemụ Topical Lidocaine 5.4%) Ph II
SP-104 (Naltrexone obere dose gbawara egbu oge) Mgbochi
RTX (resiferatoxin) Epidural injection Ph II
RTX (resiferatoxin) Ụzọ intra-articular Ph II
Nnyefe Lymphatic
Mmemme igodo (Ngosipụta) Oge Abụọ
Sofusa® mgbochi TNF (Akụkụ nke onwe RA) Ph I
Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL), Melanoma Ph I
Sofusa® mgbochi CTLA-4 (Melanoma) Ph I